Globe

IP Group plc – Spin-out company Oxford NanoLabs completes £10m fundraising

28 Mar 2008

IP Group plc (LSE: IPO) (“IP Group” or the “Company” or “Group”), the UK’s leading university intellectual property commercialisation company, is delighted to note that Oxford NanoLabs Limited (“Oxford NanoLabs” or “ONL”), a spin-out company from the University of Oxford, has successfully completed a £10 million financing round.

Oxford NanoLabs, founded in 2005, is developing nanopore technology for use in DNA sequencing, where it potentially offers significant advantages in cost and speed over existing technologies.

Following completion of the financing round, IP Group has a 35% beneficial stake in Oxford NanoLabs, valued at £19.5 million. IP Group has invested £1 million in the financing alongside investment of £1.4 million from funds managed by Top Technology Ventures Limited, a subsidiary of IP Group. The remaining £7.6 million was raised from institutional and private investors.

The fundraising will result in a total fair value gain to IP Group of £7.2 million.

For further information, please contact:

IP Group plc      0845 0742929
Alan Aubrey, Chief Executive Officer
Liz Vaughan-Adams (Communications)  020 7444 0062/07979853802

Financial Dynamics
Ben Atwell, Rob Bailhache, Sanjeev Pandya 020 7831 3113

Oxford NanoLabs
Dr Gordon Sanghera, Chief Executive Officer 0870 486 1966
Zoe McDougall (Communications)

Notes for Editors

About IP Group

IP Group is an intellectual property (IP) commercialisation company that specialises in commercialising university technology. Founded in 2001, IP Group listed on AIM in October 2003 and moved to the Official List in June 2006. It has made two acquisitions to date - Techtran, a company set up to commercialise university intellectual property under a long term contract with the University of Leeds, in 2005 and Top Technology Ventures, an investment adviser to early stage technology venture capital funds, in 2004.

IP Group has formed long-term partnerships with ten universities - the University of Oxford, King's College London, CNAP/University of York, the University of Leeds, the University of Bristol, the University of Surrey, the University of Southampton, Queen Mary (University of London), the University of Bath and the University of Glasgow.

The Company’s portfolio is diverse with exposure to five main sectors – Energy & Renewables, Healthcare & Life Sciences: Non-therapeutics, Healthcare & Life Sciences: Therapeutics, IT & Communications and Chemicals & Materials. To date, ten portfolio companies have listed on the AIM market of the London Stock Exchange, one on PLUS Markets and there have been two trade sales. IP Group also established three 'Modern-themed' subsidiaries - Modern Biosciences, Modern Water and Modern Waste. Modern Water was the first of these subsidiaries to float on AIM in June 2007.

About Oxford NanoLabs

Oxford NanoLabs is dedicated to the development of nanopore technology, to power a revolution in DNA analysis. In contrast to current technologies, nanopore-based DNA analysis has the potential to measure single molecules without the need for chemical labels, therefore avoiding the use of expensive reagents and time-consuming amplification steps.  Direct electrical measurement of the DNA sequence allows simpler instrumentation and data processing.

The Company’s proprietary BASE™ technology is being developed to use nanopores to process, identify and record DNA bases in sequence. As each base is passed sequentially through the nanopore, it binds transiently to a site within the nanopore. During binding each base generates a characteristic reduction of the electrical current through the nanopore, allowing for direct recording of the signal and simple data processing.

Oxford NanoLabs aims to use this elegant and scalable method of analysis to transform the speed and cost of DNA sequencing.  There is demand for a new generation of powerful and affordable genome sequencing technology that would facilitate a dramatic expansion in genomic research. This is characterised by the explosive interest in the race for the "$1000 genome", a common phrase that describes a tipping-point where DNA sequencing becomes so affordable and accessible that research and understanding of the genome would increase exponentially. A new, disruptive sequencing technology has the potential to enable a new era of genomic applications in medicine, the environment, agriculture and many other areas.

Oxford NanoLabs received seed funding from IP Group plc in 2005 and a further £7.75 million was raised in a private round in 2006.

For further information please visit www.oxfordnanolabs.com.